Insights
FDA & FTC compliance insights for healthcare marketing
Plain-English breakdowns of the warning letters, settlements, and regulatory shifts that determine whether your marketing can survive contact with a regulator.
Page 3 of 10
The FDA's Ongoing Warning Letter Campaign Against Stem Cell Clinics: What It Covers, Who's Getting Hit, and How to Stay Clear
The FDA has issued hundreds of warning letters to stem cell, exosome, and PRP clinics since 2017. Here's a full breakdown of what the campaign covers, the exact claim categories CBER cites, and the compliance playbook that keeps practices out of the enforcement pipeline.
The Jenny Craig FTC Precedent: Why Every Weight Loss Clinic's Testimonials Are Under Stricter Rules Than They Think
A 1997 FTC consent order set the template for how weight-loss testimonials must be disclosed. It is still the standard in 2026 - and most GLP-1 clinics, med spas, and telehealth weight-loss practices are marketing in direct violation of it without realizing it.
POM Wonderful and the FTC Substantiation Standard: What 'Competent and Reliable Scientific Evidence' Actually Means for Healthcare Marketing
Every time you say 'clinically proven,' 'scientifically backed,' or 'evidence-based,' the FTC expects you to have something specific on file. Here's what the POM Wonderful precedent actually requires - and why most practices don't meet the bar.
Botox Advertising Compliance: Why 'Botox by Nurse Smith' Might Be an FDA Violation - and What to Say Instead
Every med spa ad saying 'Botox by Nurse Smith' or 'Juvederm specials this month' is operating under rules most clinics don't know exist. Here's the full playbook for brand-name neurotoxin and filler advertising compliance.
Ozempic vs Wegovy in Your Marketing: The Brand-Name Advertising Rules Weight Loss Clinics Keep Getting Wrong
'Get Ozempic for weight loss' is one of the most common weight-loss clinic ads in 2026. It is also one of the clearest FDA prescription-drug advertising violations. Here's the full compliance framework for GLP-1 brand marketing.
FDA-Approved vs FDA-Cleared vs FDA-Registered: The Aesthetic Device Marketing Distinction That's Costing Clinics Warning Letters
Most aesthetic practices use 'FDA-approved' to describe devices that are technically FDA-cleared. The distinction matters - FDA warning letters regularly cite it. Here's the complete breakdown of the three statuses and which one applies to your equipment.
NAD+ Marketing Compliance: Why the FTC Has Your Clinic's Longevity Claims in Its Crosshairs
'Reverses aging,' 'extends lifespan,' 'restores cellular function' - the claims driving NAD+ marketing are the exact claims the FTC is currently pursuing. Here's the full compliance playbook for NAD+ IV, NAD+ injection, and NAD+ protocol marketing.
Meta Ads for Healthcare Practices: The Policy Layer on Top of FDA/FTC Rules
Your Meta ads must meet FDA rules, FTC rules, AND Meta's own healthcare advertising policy - three layers, not one. Here's the full playbook for what Meta actually enforces, how to avoid account-level issues, and how to structure ads that run reliably.
Google Ads for Healthcare Practices: Policy Certification, Restricted Categories, and What Actually Runs
Google Ads requires certifications for some healthcare categories, outright prohibits others, and enforces specific claim restrictions across all of them. Here's what the policy actually says and how to structure Google Ads campaigns that clear review and convert reliably.
Stay ahead of enforcement
Scan your marketing before regulators do.
RegenCompliance checks every word of your clinic's marketing against live FDA and FTC enforcement data - and rewrites violations automatically.